logo
A 12-time delegate shares 7 tips to make the Milken Global Conference pay dividends

A 12-time delegate shares 7 tips to make the Milken Global Conference pay dividends

It's one of my favorite times of the year: The Milken Institute Global Conference.
Why do I love it? First of all, it's the Lollapalooza of the financial world, which is the primary world in which my firm, Prosek Partners, operates.
It's also one of the few conferences in the world, like the World Economic Forum's Annual Meeting at Davos and the FII Institute's October conference, where founders and CEOs don't fly in and quickly fly out. They stay, mingle, speak, and do business for two and sometimes three full days.
A single ticket costs $50,000, or $25,000 at the early bird rate, but with that price comes exposure to the world's financial, corporate, and political leaders all in the small Beverly Hilton hotel in Los Angeles. It's almost impossible not to walk away with a new contact or insight.
And unlike the icy-cold schlep and subpar accommodations of Davos, Switzerland, or the jet lag that often comes with the FII Institute conference in Saudi Arabia, Milken is a nearly zero-friction event — no lines, no snow, no slips and falls. Instead, you get luxurious and ample hotels.
If you're new to Milken-land, here are 7 tips from a 12-time veteran.
Know thy audience - who goes to Milken
Attendees at Milken include CEOs of major financial firms and asset managers, CEOs of tech firms, some Fortune 500s and professional services firms, founders of private equity and private credit firms, institutional investors at the CIO level of pension funds, sovereign wealth funds, family offices.
And then there are those who serve them. That could be chief marketing officers and chief communications officers or heads of investor relations who are supporting their CEOs or founders at the conference.
Policy makers and politicians who care deeply about the economy and the central banking systems globally will be in tow too. This is high-level crowd geared around investing, deal-making, and the global economy.
Don't miss the health panels
A cancer survivor and major health philanthropist, Michael Milken surrounds himself with the best minds in finance, and also in healthcare.
If you want to know what is possible today with genetics, cancer care, Alzheimer's treatments, GLP-1s, preventative medicine, healthy aging, or the positive effects of psychedelics, the health content sessions are a must.
I owe Michael Milken the healthiest version of myself because I attended the "How to Live to a Healthy 100" panel almost ten years ago.
Take the private party circuit very seriously
Sometimes, the most valuable part of the conference is what is not on the agenda. There is a healthy party circuit around the Milken conference, and some of the best events are at private homes in Beverly Hills during the evenings.
These events are not publicized, and you have to be a longtime attendee to know what's happening when and where. My advice is to buddy up with a conference vet and ask for help to figure out the private event circuit. Or hire a firm that is in the know to "concierge" your experience.
Some of my favorite private events have been Goldman Sachs's women's lunch, the "Wheelhouse" event at Bette Davis's former party house, and dinner at Dan Loeb's home, founder and CEO of Third Point. If you don't maximize this aspect of the conference, you get only half the value.
Don't be afraid to approach people in the hallway
Every inch of the Milken conference is filled with someone you should get to know. For the most part, people are easy to approach.
One of my favorite memories at Milken happened 10 years ago when my business was still relatively small. I ran into David Rubenstein, the co-founder and co-chairman of Carlyle Group, in the hallway and had a ten-minute conversation, during which he spent most of the time asking about my business. What a generous man and a magic moment! Little did I know I would represent his firm a few years later.
Prepare to struggle for meeting space
Meeting space at the Beverly Hilton is reserved for those who pay $250,000 at minimum to be sponsors of Milken. If that isn't you, you'll struggle to find a place for a meeting on the hotel grounds. There is a restaurant and a café on-site, but lines are long and there's no guarantee they'll have space when you need it.
The trick is to reserve a room and/or meeting space at the hotels within walking distance from the Hilton like The Peninsula and the Waldorf Astoria — but you have to do so a year in advance. If you are planning for Milken 2026, book those rooms right at the end of this conference season. Most hotels will move their beds out if you want to transform the space into a meeting room.
Remember that Milken is a nonprofit
The Milken conference can be so commercially productive that many people forget what the Milken Institute actually is — a nonprofit that supports several important educational and health causes.
This year, Michael Milken will open his Center for Advancing the American Dream in Washington, DC to help make sure the American Dream stays alive. Take a moment to study what the Milken Institute does and take advantage of the purpose-driven aspects of being part of the Milken world.
Arrive with a game plan
Make sure you have a "monetizing the mingle" strategy before you go to Milken. Whether you are a single-ticket holder or a sponsor, you are spending a truckload of time and money to attend, so you need goals, a strategy, and a plan to maximize your time on the ground.
Are you trying to meet investors? What kind? Where do they go at the conference? Are you trying to increase your profile? If so, what reporters can you meet on the ground? Can you break news there and secure a coveted slot on CNBC or Bloomberg at the conference?
Too many people I know show up with no plan and waste precious time and money. Don't be one of them. If you're doing it right, your return on time and money should be in the green. See you in LA!
Jennifer Prosek is managing partner of Prosek Partners

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Penn Entertainment responds to ISS report
Penn Entertainment responds to ISS report

Business Insider

time2 days ago

  • Business Insider

Penn Entertainment responds to ISS report

Penn Entertainment (PENN) made the following statement in response to the report issued by Institutional Shareholder Services related to the company's 2025 annual meeting of shareholders on June 17: 'The ISS report confirms that two director seats are up for election at the 2025 Annual Meeting and that PENN and HG Vora have nominated and are recommending the same two highly-qualified candidates – Johnny Hartnett and Carlos Ruisanchez. ISS recognizes the open-mindedness with which PENN evaluated HG Vora's director candidates, noting: 'To its credit, the board appears to have given serious consideration to all three dissident nominees, and was open to accepting two of these nominees as its own.' PENN encourages all shareholders to vote for Messrs. Hartnett and Ruisanchez for election and looks forward to welcoming them to the Board. Following the Annual Meeting, 75% of PENN's directors will have joined the Board since 2019. In reaching its conclusions however, the ISS report fails to reflect a realistic view of William Clifford's candidacy. We remind shareholders that, during his time as PENN's CFO, Mr. Clifford advocated against key initiatives that were critical to succeeding in a competitive market. Following Mr. Clifford's departure in 2013 as PENN's CFO, these changes were implemented under the publicly announced P30 program and resulted in meaningful margin improvement. Further, during his interviews with PENN's Nominating and Corporate Governance Committee, Mr. Clifford demonstrated antiquated views of a rapidly changing industry, and the same posture of resistance to exploring value-generating solutions, which we believe would hinder constructive decision-making. PENN attempted multiple resolutions with HG Vora, but all of our resolution attempts were rejected. Given HG Vora's violation of its institutional waivers by multiple state gaming regulators, our ability to allow HG Vora to influence the governance of the Company beyond the evaluation of the nominees was expressly prohibited. We appreciate the feedback and advice we have received from our shareholders in advance of this year's Annual Meeting. We want to assure shareholders that we understand and share their focus on ensuring that PENN's Board of Directors is optimally comprised to oversee the Company's execution on a strategic plan to drive shareholder value. The Board and management team remain committed to creating value for all shareholders and will continue to take actions in support of that objective.'

The British Medical Journal Publishes Study Results on Sacituzumab Tirumotecan for Previously Treated EGFR-Mutant Advanced NSCLC
The British Medical Journal Publishes Study Results on Sacituzumab Tirumotecan for Previously Treated EGFR-Mutant Advanced NSCLC

Yahoo

time2 days ago

  • Yahoo

The British Medical Journal Publishes Study Results on Sacituzumab Tirumotecan for Previously Treated EGFR-Mutant Advanced NSCLC

CHENGDU, China, June 6, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", today announced that results from its registrational study (OptiTROP-Lung03) evaluating sacituzumab tirumotecan (sac-TMT) versus docetaxel in patients with previously treated advanced EGFR-mutant non-small cell lung cancer (NSCLC) have been published in The British Medical Journal (impact factor: 93.6). These data were also presented as an oral presentation in the Lung Cancer—Non–Small Cell Metastatic session (Abstract #8507) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Based on the encouraging data from this study, sac-TMT was approved for marketing by the National Medical Products Administration (NMPA) for the treatment of adult patients with epidermal growth factor receptor (EGFR) mutant-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-tyrosine kinase inhibitor (TKI) therapy and platinum-based chemotherapy in March 2025. This marks the first global approval of a TROP2 ADC for a lung cancer indication. The published results are based on OptiTROP-Lung03, an open-label, randomized, multicenter registrational study evaluating the efficacy and safety profile of sac-TMT monotherapy versus docetaxel for the treatment of patients with locally advanced or metastatic EGFR-mutant NSCLC who have failed after treatment with an EGFR-TKI and platinum-based chemotherapy. A total of 137 patients with advanced EGFR-mutant NSCLC who had progressed after EGFR-TKI and platinum-based chemotherapy were randomized (2:1) to receive sac-TMT (5 mg/kg once every 2 weeks) or docetaxel (75 mg/m2 once every 3 weeks) until disease progression, intolerable toxicity or other reason for discontinuation, with a median follow-up time of 12.2 months (Data cutoff date: December 31, 2024). Sac-TMT achieved statistically significant and clinically meaningful outcomes compared to docetaxel: Confirmed objective response rate (ORR) (As assessed by blinded independent review committee (BIRC): 45% (95% CI, 35-56) vs 16% (95% CI, 7-30). Median progression-free survival (PFS) (As assessed by BIRC: 6.9 months [sac-TMT; 95% CI, 5.4-8.2] vs 2.8 months [docetaxel; 95% CI, 1.6-4.1], hazard ratio (HR)= 0.30 [range, 0.20 -0.46], one-sided p<0.0001; as assessed by investigator (INV): 7.9 months [sac-TMT; 95% CI, 6.2-9.5] vs 2.8 months [docetaxel; 95% CI, 1.5-3.8], HR=0.23 [95% CI, 0.15-0.36], one-sided p<0.0001). With 36.4% of patients in docetaxel group crossing over to receive sac-TMT, median overall survival (OS) was not reached (NR) for both groups (HR=0.49; 95% CI, 0.27-0.88; one-sided p=0.007). The median OS analysed by pre-specified rank-preserving structural failure time (RPSFT) model adjusted for crossover was 9.3 months for docetaxel and NR for sac-TMT (HR=0.36; 95% CI, 0.20-0.66). Efficacy benefit favored patients with sac-TMT over docetaxel across all pre-specified subgroups, including prior EGFR-TKI therapy, brain metastases, EGFR mutation type, etc. Grade ≥ 3 treatment-related adverse events (TRAEs) occurred in 56.0% of patients in sac-TMT group vs 71.7% in docetaxel group. The results demonstrated that sac-TMT monotherapy achieved statistically significant and clinically meaningful improvements in objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) compared to docetaxel, with a manageable safety profile. Sac-TMT is being extensively studied in the NSCLC field. Covering treatment settings from later-line therapy to early-stage postoperative adjuvant therapy, including both monotherapy and combination regimens. Currently, five company-led registrational clinical studies for sac-TMT in NSCLC are underway in China. Meanwhile, Merck Sharp & Dohme(the tradename of Merck & Co., Inc., Rahway, NJ, USA)is also conducting five global Phase III clinical trials of sac-TMT for NSCLC in regions where it has exclusive rights. Professor Li Zhang, National Lead Principal Investigator, Medical Oncologist and Deputy Director of the Lung Cancer Research Centre at Sun Yat-Sen University, stated: "EGFR mutation is the most common driver alteration in NSCLC. The prevalence of EGFR mutations reaches 28.2% among NSCLC patients in China. Although third-generation EGFR-TKIs have become the standard of care for advanced EGFR-mutant NSCLC and may significantly improve PFS, acquired resistance remains inevitable. Combining EGFR-TKIs with chemotherapy can offer additional survival benefits to some patients, but this approach is limited by safety concerns and may compromise future treatment options, posing significant clinical challenges. The publication of the OptiTROP-Lung03 study in the British Medical Journal marks a major milestone—not only highlighting international recognition of this study outcomes in lung cancer, but also demonstrating the global competitiveness of sac-TMT as a novel TROP2 ADC." Dr. Michael Ge, CEO of Kelun-Biotech, commented: "We are thrilled to see the OptiTROP-Lung03 study published in a top-tier journal. Currently, EGFR-TKIs and chemotherapy remain the standard of care for patients with EGFR-mutant advanced NSCLC, but the challenge of increasing efficacy with manageable tolerability. The results from OptiTROP-Lung03 highlight significant survival benefits with manageable safety profile and suggest that sac-TMT could emerge as a new standard of care for this population. We remain committed to working with our partners to establish sac-TMT as a new standard of care for this patient population and improve outcomes for lung cancer patients worldwide." Registrational Study Led by Kelun-Biotech OptiTROP-Lung03: Sac-TMT monotherapy versus docetaxel for locally advanced or metastatic EGFR-mutant NSCLC after treatment failure with EGFR-TKI and platinum-containing chemotherapy; OptiTROP-Lung04: Sac-TMT monotherapy versus pemetrexed in combination with platinum for locally advanced or metastatic non-squamous NSCLC with EGFR mutations that have failed EGFR-TKI therapy; OptiTROP-Lung05: Sac-TMT combined with pembrolizumab versus chemotherapy combined with pembrolizumab for first-line treatment of PD-L1-positive locally advanced or metastatic NSCLC; OptiTROP-Lung06: Sac-TMT combined with pembrolizumab versus chemotherapy combined with pembrolizumab for the first-line treatment of PD-L1-negative locally advanced or metastatic non-squamous NSCLC; OptiTROP-Lung07: First-line treatment of locally advanced or metastatic NSCLC with EGFR mutations by sac-TMT in combination with ositinib. Registrational Study Led by MSD NSCLC not achieving a pCR after neoadjuvant therapy followed by surgery. NSCLC expressing PD-L1 >50% pre-treated NSCLC with EGFR mutations or other genomic alterations EGFR-mutated, advanced non-squ NSCLC progressed on prior EGFR-TK metastatic sg NSCLC About sac-TMT Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, BC, gastric cancer (GC), gynecological tumors, among others. Sac-TMT is developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells. In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc., Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (includes Mainland China, Hong Kong, Macao, and Taiwan). To date, two indications for sac-TMT have been approved and marketed in China for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting) based on the OptiTROP-Breast01 study and EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy based on the OptiTROP-Lung03 study. Sac-TMT became the first domestic ADC with global intellectual property rights to be fully approved for marketing. It is also the world's first TROP2 ADC to be approved for marketing in a lung cancer indication. In addition, two new indication applications for sac-TMT for the treatment of adult patients with EGFR-mutant locally advanced or metastatic NSCLC who progressed after treatment with EGFR-TKI therapy and with unresectable locally advanced, metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) BC who have received prior endocrine therapy and other systemic treatments in the advanced or metastatic setting were accepted by the National Medical Products Administration (NMPA), and were reviewed via the priority review and approval process. As of today, the Company has initiated 8 registrational clinical studies in China. MSD has initiated 14 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or with pembrolizumab or other agents for several types of cancer. These studies are sponsored and led by MSD. About Kelun-Biotech Kelun-Biotech( a holding subsidiary of Kelun Pharmaceutical ( which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 3 projects have been approved for marketing, 1 project is in the NDA stage, and more than 10 projects are in the clinical stage. The company has established one of the world's leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage, and multiple ADC and novel coupled drug products in clinical or preclinical research stage. For more information, please visit Media: klbio_pr@ View original content to download multimedia: SOURCE Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

‘It's just a different world now': Dropbox CEO Drew Houston slams return-to-office mandates
‘It's just a different world now': Dropbox CEO Drew Houston slams return-to-office mandates

San Francisco Chronicle​

time2 days ago

  • San Francisco Chronicle​

‘It's just a different world now': Dropbox CEO Drew Houston slams return-to-office mandates

In a sharp rebuke of corporate return-to-office policies, Dropbox CEO Drew Houston likened the push to bring employees back into physical workspaces to reviving outdated institutions. 'Forcing people back to the office is probably going to be like trying to force people back into malls and movie theaters,' Houston said during an episode of Fortune's Leadership Next podcast on Wednesday. 'Nothing wrong with the movie theater, but it's just a different world now.' JPMorgan, in particular, has faced criticism from employees after CEO Jamie Dimon insisted on a five-day office week, dismissing remote work as ineffective for collaboration and mentorship. 'You can't learn working from your basement,' Dimon said in a recent Bloomberg interview. 'We can be a lot less dumb than forcing people back into a car three days a week or whatever, to literally be back on the same Zoom meeting they would have been at home,' he said. 'There's a better way to do this.' Nearly half of employees who work from home at least occasionally say they'd be unlikely to stay in their current job if remote work were eliminated, according to a recent Pew Research Center survey. Dropbox pivoted to a 'virtual first' model in 2020, and now operates under a 90/10 model — employees work remotely 90% of the time, with the remainder reserved for periodic in-person gatherings. Houston emphasized the need to evolve remote work strategies beyond the early pandemic's reactive model. 'Version two, version three of this is going to be a lot better than the version point-five that we had in the pandemic,' he said. 'If you trust people and treat them like adults, they'll behave like adults,' he told Fortune in 2023. 'Trust over surveillance.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store